Literature DB >> 12826823

Role of cardiac power in heart failure.

Gad Cotter1, Simon G Williams, Zvi Vered, Lip Bun Tan.   

Abstract

The heart is a muscular mechanical pump with an ability to generate both flow (cardiac output) and pressure. The product of flow output and systemic arterial pressure is the rate of useful work done, or power output. Cardiac pumping capability can be defined as the cardiac power output (CPO(max)) achieved by the heart during maximal stimulation. Cardiac reserve is the increase in power output as the cardiac performance is increased from the resting to the maximally stimulated state. Recently, several studies have shown that CPO(max), a direct indicator of overall cardiac function, measured directly or as an approximation, is a major determinant of exercise capacity and a most powerful predictor of prognosis for patients with chronic heart failure. The same holds true in acute heart failure, where it is also useful in subclassifying the conditions to select the appropriate treatment.

Entities:  

Mesh:

Year:  2003        PMID: 12826823     DOI: 10.1097/00001573-200305000-00007

Source DB:  PubMed          Journal:  Curr Opin Cardiol        ISSN: 0268-4705            Impact factor:   2.161


  22 in total

Review 1.  Differential signaling in presynaptic neurotransmitter release.

Authors:  Wim E J M Ghijsen; A G Miriam Leenders
Journal:  Cell Mol Life Sci       Date:  2005-05       Impact factor: 9.261

2.  Prognostic role of cardiac power index in ambulatory patients with advanced heart failure.

Authors:  Justin L Grodin; Wilfried Mullens; Matthias Dupont; Yuping Wu; David O Taylor; Randall C Starling; W H Wilson Tang
Journal:  Eur J Heart Fail       Date:  2015-04-28       Impact factor: 15.534

Review 3.  [Use of vasopressors and inotropics in cardiogenic shock].

Authors:  H Lemm; S Dietz; M Janusch; M Buerke
Journal:  Herz       Date:  2017-02       Impact factor: 1.443

Review 4.  Pathophysiology, diagnosis, and treatment of infarction-related cardiogenic shock.

Authors:  M Buerke; H Lemm; S Dietz; K Werdan
Journal:  Herz       Date:  2011-03       Impact factor: 1.443

5.  Abnormal haemodynamic response to exercise in heart failure with preserved ejection fraction.

Authors:  Paul S Bhella; Anand Prasad; Katja Heinicke; Jeff L Hastings; Armin Arbab-Zadeh; Beverley Adams-Huet; Eric L Pacini; Shigeki Shibata; M Dean Palmer; Bradley R Newcomer; Benjamin D Levine
Journal:  Eur J Heart Fail       Date:  2011-10-05       Impact factor: 15.534

Review 6.  New approaches to therapy of cancers of the stomach, colon and pancreas based on peptide analogs.

Authors:  A V Schally; K Szepeshazi; A Nagy; A M Comaru-Schally; G Halmos
Journal:  Cell Mol Life Sci       Date:  2004-05       Impact factor: 9.261

Review 7.  [Cardiogenic shock: pathophysiology, clinics, therapeutical options and perspectives].

Authors:  R Prondzinsky; K Werdan; M Buerke
Journal:  Internist (Berl)       Date:  2004-03       Impact factor: 0.743

8.  Quantification of the impaired cardiac output response to exercise in heart failure: application of a non-invasive device.

Authors:  Jonathan Myers; Pradeep Gujja; Suresh Neelagaru; Leon Hsu; Daniel Burkhoff
Journal:  J Sports Sci Med       Date:  2009-09-01       Impact factor: 2.988

9.  Mavacamten preserves length-dependent contractility and improves diastolic function in human engineered heart tissue.

Authors:  Lorenzo R Sewanan; Shi Shen; Stuart G Campbell
Journal:  Am J Physiol Heart Circ Physiol       Date:  2021-01-15       Impact factor: 4.733

10.  Hemodynamic variables and mortality in cardiogenic shock: a retrospective cohort study.

Authors:  Christian Torgersen; Christian A Schmittinger; Sarah Wagner; Hanno Ulmer; Jukka Takala; Stephan M Jakob; Martin W Dünser
Journal:  Crit Care       Date:  2009-10-02       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.